anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of genes, and particularly relates to a KIF11 gene mutant and application thereof. Specifically disclosed are nucleic acids comprising a fragment of interest having a c.2680c > T mutation compared to the wild-type KIF11 gene. A polypeptide having a p.gln894ter mutation compared to wild-type KIF 11. A gene mutation having a c.2680c > T mutation compared to a wild-type KIF11 gene. The application of the mutant biological model in preparing a screening preparation for microcephaly, chorioretinopathy, lymphedema and mental retardation. A screening reagent for microcephaly, without choroidal retinopathy, lymphedema and mental retardation comprises a reagent capable of detecting a KIF11 gene mutant. The present invention provides new mutational sites related to microcephaly, chorioretinopathy, lymphedema and mental retardation, provides a new scheme for the diagnosis and treatment of the disease, and provides related medicines for preventing and treating the disease.
The child was given a comfortable position. A nurse independent from the study assessed the child with the Child Anxiety Scale-Condition (CAS-D), Child Fear Scale, and Visual Analogue Scale (VAS) before the procedure. The child was fitted with virtual reality goggles and a video of the child's choice was shown. One of the videos was a video of visiting animals in the zoo, while the other video was an aquarium video containing colorful fish and creatures under the sea. The zoo visit video is 3 minutes 51 seconds and the aquarium visit video is 11 minutes 55 seconds. Two minutes after the child started watching the video, peripheral catheter insertion was started. During the procedure, the same nurse, who was independent of the study, assessed the child with the Child Anxiety Scale-Condition(CAS-D), Child Fear Scale, and Visual Analogue Scale (VAS) and recorded the duration of the procedure and the child's crying (how many seconds it lasted).
PROBLEM TO BE SOLVED: To obtain the subject composition capable of eluting sebum accumulated in hair follicles without applying a mechanical force such as rubbing by adjusting to have a prescribed range of a boundary tension value to an oleic acid. SOLUTION: This sebum remover composition has a boundary tension value to oleic acid at 25 deg.C is 0-0.05 mN/m. The composition preferably contains (A) an inorganic salt, (B) a nonionic surfactant and (C) a cation surfactant and is preferably adjusted by a suitable amount so as the boundary tension value to be the range. For instance, each of components A-C is preferably mixed in an amount of 0.001-20 wt.% based on a total of the composition and a weight ratio of (A/B)=(1/2,000)-(2,000/1) and (B/C)=(1/2,000)-(2,000/1). By the method, sebum, etc., accumulated in hair follicles, etc. can readily be eluted and further sebum accumulated between fibers can also readily be eluted.
High carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
FIELD: medicine, ophthalmology. SUBSTANCE: method deals with introducing medicinal preparations into parabulbar fiber. It is distinguished by the fact that antibacterial and steroid preparations are dissolved in polyglukin at 1:1-2 ratio right before injection. Moreover, the volume of injected solution should not exceed 1.0 ml. The method suggested enables to increase efficiency and shorten the terms of therapy, decrease toxic action of antibacterial and steroid preparations. EFFECT: higher efficiency of therapy. 1 cl, 3 ex
PURPOSE OF REVIEW: Review the current evidence on biomarkers for bipolar disorder in the older adults. We conducted a systematic search of PubMed MEDLINE, PsycINFO, and Web of Science databases using the MeSH search terms "Biomarkers", "Bipolar Disorder", "Aged" and and "Aged, 80 and over". Studies were included if they met the following criteria: (1) the mean age of the study population was 50 years old or older, (2) the study included patients with bipolar disorder, and (3) the study examined one type of biomarkers or more including genetic, neuroimaging, and biochemical biomarkers. Reviews, case reports, studies not in English and studies for which no full text was available were excluded. A total of 26 papers were included in the final analysis.
RECENT FINDINGS: Genomic markers of bipolar disorder in older adults highlighted the implication of serotonin metabolism, while the expression of genes involved in angiogenesis was dysregulated. Peripheral blood markers were mainly related with low grade inflammation, axonal damage, endothelial dysfunction, and the dysregulation of the HPA axis. Neuroanatomical markers reflected a dysfunction of the frontal cortex, a loss of neurones in the anterior cingulate cortex and a reduction of the hippocampal volume (in patients older than 50 years old). While not necessarily limited to older adults, some of them may be useful for differential diagnosis (neurofilaments), disease staging (homocysteine, BDNF) and the monitoring of treatment outcomes (matrix metalloproteinases). Our review provides a comprehensive overview of the current evidence on biomarkers for bipolar disorder in the older adults. The identification of biomarkers may aid in the diagnosis, treatment selection, and monitoring of bipolar disorder in older adults, ultimately leading to improved outcomes for this population. Further research is needed to validate and further explore the potential clinical utility of biomarkers in this population.
A method to treat disorders characterized by production of soluble cytokine receptor molecules, e.g. soluble tumor necrosis factor receptors (sTNFR). Sa id diseases comprise many types of cancer and certain diseases such as HIV- infection. In the preferred embodiment, the patient's blood is passed throug h a column having antibodies immobilized thereon, which bind to and remove the  sTNRF molecules, and then led back into the patient, according to the UltraPheresis (TM) method. The process can be performed alone or in combination with other therapies, e.g. administration of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents or by radiation.
Upregulation of ADAMTS-4 has been reported to have an important role in lung injury, and ADAMTS-4 expression is regulated by miR-126a-5p in abdominal aortic aneurysms. The aim of this study was to investigate whether miR-126a-5p/ADAMTS-4 plays a role in influenza-virus-induced lung injury. Lung fibroblasts were infected with H1N1 influenza virus to detect changes in miR-126a-5p and ADAMTS-4 expression, and cell viability was measured by CCK-8 assay. Inflammatory factors and matrix protease levels were examined using ELISA kits, and cell apoptosis was assessed by measuring the levels of apoptosis-related proteins. A dual luciferase assay was used to verify the regulatory relationship between miR-126a-5p and ADAMTS-4. H1N1 influenza virus reduced fibroblast viability, inhibited miR-126a-5p expression, and promoted ADAMTS-4 expression. Overexpression of miR-126a-5p attenuated the cellular inflammatory response, apoptosis, matrix protease secretion, and virus replication. Luciferase reporter assays revealed that miR-126a-5p inhibited ADAMTS-4 expression by targeting ADAMTS-4 mRNA. Further experiments showed that overexpression of ADAMTS-4 significantly reversed the inhibitory effects of miR-126a-5p on fibroblast inflammation, apoptosis, matrix protease secretion, and virus replication. Upregulation of miR-126a-5p inhibits H1N1-induced apoptosis, inflammatory factors, and matrix protease secretion, as well as virus replication in lung fibroblasts.
Intensive lifestyle intervention at a tertiary care rehabilitation center. Treatment included changes in both dietary habits (calori restriction) and physical activity with particularly high intensity the first 3 months.
The invention belongs to the technical field of medicinal chemistry, and particularly relates to an application of a naphthalimide-polyamine derivative and cyclosporine A in preparation of an antitumor medicament. The invention provides an application of a naphthalimide-polyamine derivative combined with cyclosporine A in preparing an anti-tumor medicament by combining the naphthalimide-polyamine derivative and the cyclosporine A. The test result proves that compared with the single medicine group, the combined medicine can obviously inhibit the in-vivo metastasis of the liver cancer cells and obviously improve the anti-tumor activity of the single medicine group. Meanwhile, compared with a single medicine group, the combined administration can improve the survival rate of tumor-bearing mice. The combined drug can obviously reduce the dosage of the two drugs, obviously improve the anti-tumor effect and lower the toxicity to normal liver cells than liver cancer cells. The combined administration of cyclosporin A and the naphthalimide-polyamine derivative 6c may be a novel method for treating patients with liver cancer.
BACKGROUND: Bowel obstruction is a mechanical or functional blockade of intestinal contents from evacuation to the adjacent distal bowel or external environment. It poses significant morbidity and mortality in both high-income and low-to-middle-income countries. Ileosigmoid knotting is a special form of obstruction where the small bowel often ileum wraps around the sigmoid colon or vice versa. It is the severest form of bowel obstruction, involving both the small and large bowels in a compound manner. It is common where sigmoid volvulus is common and geographic areas with a bulky diet.
METHODS: An institution-based retrospective cohort study was employed among purposively selected 40 surgical patients with ileosigmoid knotting records from July 2020 to July 2023 at Jimma University Medical Center. To estimate and compare the survival probabilities, the Kaplan-Meir method and log-rank test were used. A Cox-regression analysis was fitted to identify independent predictors of time to death.
RESULTS: Among a cohort of 40 patients followed for 347 person-days at Jimma University Medical Center, 11 (27.5%) had died. The overall incidence rate of death was 3.2 (95% CI 1.8, 5.7) per 100 person-days. In multivariable Cox-regression analysis, age (AHR = 1.15; 95% CI: 1.04-1.28), shock at presentation (AHR = 30.50: 95% CI 1.25-742.54), comorbidities (AHR = 5.81; 95% CI 1.19-28.23), pulse rate intraoperatively (AHR = 1.19; 95% CI: 1.01-1.40), postoperative pulse rate (AHR = 1.07; 95% CI: 1.01-1.14) were independently associated with time to death.
CONCLUSION: The incidence of death among surgical patients with ileosigmoid knotting was high and also had a shorter median survival time. Age, shock at presentation, comorbidities, pulse rate intraoperatively, and postoperative pulse rate were found to be statistically significant predictors of time to death and outcome among surgical patients with Ileosigmoid knotting.
This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created and/or the liquid is predisposed to their presence (e.g., conditioned)) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred. The continuous process causes at least one liquid to flow into, through and out of at least one trough member, such liquid being processed, conditioned and/or effected in said trough member(s). Results include constituents formed in the liquid including micron-sized particles and/or nanoparticles (e.g., metallic-based nanoparticles) of novel size, shape, composition, zeta potential and properties present in a liquid.
In this paper, we described technique of platelet rich plasma injection into the olfactory cleft in a 22-year-old female with 24-month post-COVID-19 anosmia. The technique starts with the blood extraction and the isolation of PRP through a 10-min centrifugation. The supernatant was injected in nasal regions after a local anesthesia through a 0° rigid optic. Several points of .2-.5 mL were performed in the nasal septum in regard of the head of the middle turbine and in the head of the middle turbine in both sides. The baseline threshold, discrimination, and identification scores were 1, 8, and 0, and the Olfactory Disorder Questionnaire score was 51, respectively. The injection of PRP in olfactory cleft was done without complication and mild pain. The patient perception of recovery of smell sense occurred at 3-week post-injection. From this time, the smell sense progressively improved to the 2-month consultation. At 2-month post-injection, the TDI scores reached 16, 16, and 16 (48), while the Olfactory Disorder Questionnaire was 73. The injection of PRP into the olfactory cleft appears to be a safe and easiness new approach that may improve the recovery of smell sense. Future controlled studies are needed.
FIELD: genetic engineering, virology. SUBSTANCE: invention claims c-DNA for preparing recombinant tickborne encephalitis virus. c-DNA comprises encoding and non-encoding sequences given in the description. Encoding sequence can involve additional G before the position 1. c-DNA encodes amino acid sequences with modifications and exchanges given in the description. Invention ensures to obtain vaccines against tick- borne encephalitis. EFFECT: valuable properties of c-DNA. 8 cl, 21 dwg, 4 tbl, 13 ex
The aim of this study was to estimate the genetic parameters of the reproductive performance of the Azawak zebu, bred on station during the period 1981 to 2007, in order to contribute to the implementation of an effective selection programme for improving the zootechnical performance of cattle herds. The data contained records of 2453 calvings from 650 Azawak cows, daughters of 55 bulls, all bred at the Toukounous experimental centre (Niger). Non-genetic factors were evaluated using linear mixed models and genetic parameters were estimated using REML procedures with a multi-trait animal model. The effects of year and calving rank were significant (P < 0.001) for the three reproductive traits studied. Heritability was low for age at first calving (h2 = 0.09 ± 0.03) and calf birth weight (h2 = 0.07 ± 0.03). It was moderate for calving interval (h2 = 0.30 ± 0.04) indicating the possibility of genetic improvement of this trait by selection. Repeatability estimates for calf birth weight and calving interval were 0.10 ± 0.02 and 0.42 ± 0.03 respectively. Calving interval had very strong and significant genetic correlations with age at first calving (0.84 ± 0.08) and calf birth weight (-0.40 ± 0.20). There was also a significantly favourable genetic correlation between calf weight at birth and age at first calving (-0.32 ± 0.25), implying a simultaneous improvement in all three reproductive traits through selection. An increase in heritability of calf birth weight was observed after the active phase of the program, reflecting an overly open selection scheme. These genetic parameter estimates suggest that the three reproductive traits could be used in selection index with the aim to improve the three reproductive traits of Azawak cattle.
Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.
Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg), administered intravenously Day 1 of a 21-day cycle and fosbretabulin (60 mg/m2) on Days 7, 14, and 21 for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) on Day 1 and fosbretabulin on Days 1, 7 and 14 every 3 weeks until progression or until 12 months from randomization.
Adjustment problems are highly prevalent among students around the world (Conley et.al., 2013). Unfortunately only half of students in need receive psychological help (Eisenberg et al., 2018). For these reasons, there is a need to develop and evaluate new, more scalable forms of treatment for students with adjustment disorder - such as internet therapeutic programs. Therefore the aim of the present research is to evaluate the effectiveness of online cognitive-behavioural therapy intervention. Mediators of obtained changes will also be evaluated. The present study has a potential for the development of a scalable, well researched treatment option for students experiencing adjustment disorder - internet psychological intervention.
A modified frequently sampled intravenous glucose tolerance (mFSIGT) test was used. On day 0, baseline 22 time point mFSIGT was performed. Subjects were then treated with cholecalciferol (vitamin D3) supplementation - 10,000 IU/day - for 28 consecutive days. mFSIGT was then repeated measuring glucose, insulin and c-peptide at all time points. 25-OH vitamin D, PTH, and calcium were also measured at time point 0 pre and post vitamin D supplementation. Data was analyzed using the Bergman/Boston minimal model for insulin homeostasis with MinMod Millennium software.
A method of purifying radiochemical species (e.g., radiopharmaceuticals) using thin layer chromatography (TLC) plates includes loading one or more TLC plates with a sample containing the radiochemical species to be purified. The one or more TLC plates are then developed with a mobile phase. The one or more developed TLC plates are then imaged to obtain radioactivity image(s) of the one or more TLC plates. Optional UV images may also be obtained using the same imaging platform. The location of the radiochemical species on the one or more TLC plates is identified from the radioactivity image(s). The radiochemical species on the one or more TLC plates is/are removed at the identified locations. Removal may be accomplished using a mechanical process such as scraping or punching. Alternatively, non-destructive techniques may be employed to remove the radiochemical species from the TLC plate(s).
The effectiveness of NUVIGIL in improving wakefulness in patients with excessive sleepiness (ES) associated with narcolepsy was established in one 12-week, multi-center, placebo-controlled, parallel-group, double-blind study of outpatients who met the ICSD criteria for narcolepsy. A total of 196 patients were randomized to receive NUVIGIL 150 or 250 mg/day, or matching placebo. The ICSD criteria for narcolepsy include either 1) recurrent daytime naps or lapses into sleep that occur almost daily for at least three months, plus sudden bilateral loss of postural muscle tone in association with intense emotion (cataplexy), or 2) a complaint of excessive sleepiness or sudden muscle weakness with associated features: sleep paralysis, hypnagogic hallucinations, automatic behaviors, disrupted major sleep episode; and polysomnography demonstrating one of the following: sleep latency less than 10 minutes or rapid eye movement (REM) sleep latency less than 20 minutes and a Multiple Sleep Latency Test (MSLT) that demonstrates a mean sleep latency of less than 5 minutes and two or more sleep onset REM periods and no medical or mental disorder accounts for the symptoms. For entry into these studies, all patients were required to have objectively documented excessive daytime sleepiness, via MSLT with a sleep latency of 6 minutes or less and the absence of any other clinically significant active medical or psychiatric disorder. The MSLT, an objective polysomnographic assessment of the patient’s ability to fall asleep in an unstimulating environment, measured latency (in minutes) to sleep onset averaged over 4 test sessions at 2-hour intervals. For each test session, the subject was told to lie quietly and attempt to sleep. Each test session was terminated after 20 minutes if no sleep occurred or immediately after sleep onset.

The primary measures of effectiveness were: 1) sleep latency as assessed by the Maintenance of Wakefulness Test (MWT) and 2) the change in the patient’s overall disease status, as measured by the Clinical Global Impression of Change (CGI-C) at the final visit (See CLINICAL TRIALS, OSA section above for a description of these measures). Each MWT test session was terminated after 20 minutes if no sleep occurred or immediately after sleep onset in this study. 

Patients treated with NUVIGIL showed a statistically significantly enhanced ability to remain awake on the MWT at each dose compared to placebo at final visit [Table 1]. A statistically significant greater number of patients treated with NUVIGIL at each dose showed improvement in overall clinical condition as rated by the CGI-C scale at final visit [Table 2].

The two doses of NUVIGIL produced statistically significant effects of similar magnitudes on the CGI-C. Although a statistically significant effect on the MWT was observed for each dose, the magnitude of effect was observed to be greater for the higher dose.

Nighttime sleep measured with polysomnography was not affected by the use of NUVIGIL.
Surgical site infection (SSI) after posterior open lumbar fusion (POLF) is a major concern for both surgeons and patients. We sought to explore whether local application of vancomycin could decrease the rate of SSI. We reviewed the clinical data of patients who underwent POLF between June 2015 and June 2022 at 3 spinal centers. Patients were divided into those who received local vancomycin (vancomycin group) and those who did not (non-vancomycin group). The SSI rates at 12 months postoperatively were compared between the 2 groups. Although a trend toward a lower infection rate was observed in the vancomycin group than in the non-vancomycin group; the difference was not statistically significant (3.6% vs 5.5%, P = .121). However, we found that the postoperative SSI rate was significantly lower in the vancomycin group than in the non-vancomycin group (4.9% vs 11.4%, P = .041) in patients ≥ 2 fused segments, while there was no significant difference in postoperative SSI rate in patients with single fusion segment (3.1% vs 3.6%, P = .706). The logistic regression analysis indicated that the SSI rate in the non-vancomycin group was approximately 2.498 times higher than that in the vancomycin group (P = .048, odds ratio: 2.498, 95% confidence interval: 1.011-6.617) in patients with ≥2 fused segments. In SSI patients with confirmed pathogens, the SSI rate of Gram-negative bacteria in the vancomycin group was significantly higher than that in the non-vancomycin group (10/14 [71.4%] vs 5/22 [31.8%]), whereas the SSI rate of Gram-positive bacteria in the vancomycin group was significantly lower than that in the non-vancomycin group (4/14 [28.6%] vs 15/22 [68.2%]). Local administration of vancomycin is recommended in patients with ≥2 fused segments as it may facilitate to reduce the postoperative rate of SSI after POLF. Additionally, the local use of vancomycin can decrease the Gram-positive bacterial infections but is not effective against Gram-negative infections, which indirectly leads to an increase in the proportion of Gram-negative infections in SSI patients with confirmed pathogens.